← Back to Search
Malignant Pleural Mesothelioma: An Update On Investigation, Diagnosis And Treatment
A. Bibby, S. Tsim, N. Kanellakis, Hannah L. Ball, D. Talbot, K. Blyth, N. Maskell, I. Psallidas
Published 2016 · Medicine
Download PDFAnalyze on Scholarcy
Malignant pleural mesothelioma is an aggressive malignancy of the pleural surface, predominantly caused by prior asbestos exposure. There is a global epidemic of malignant pleural mesothelioma underway, and incidence rates are predicted to peak in the next few years. This article summarises the epidemiology and pathogenesis of malignant pleural mesothelioma, before describing some key factors in the patient experience and outlining common symptoms. Diagnostic approaches are reviewed, including imaging techniques and the role of various biomarkers. Treatment options are summarised, including the importance of palliative care and methods of controlling pleural effusions. The evidence for chemotherapy, radiotherapy and surgery is reviewed, both in the palliative setting and in the context of trimodality treatment. An algorithm for managing malignant pleural effusion in malignant pleural mesothelioma patients is presented. Finally new treatment developments and novel therapeutic approaches are summarised. This article on mesothelioma describes pathogenesis, symptoms, diagnostic approaches and treatment options http://ow.ly/cjkb305aQGz
This paper references
Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
W. Richards (2006)
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
Global Magnitude of Reported and Unreported Mesothelioma
Eun-Kee Park (2011)
Is there a role for pre-operative contrast-enhanced magnetic resonance imaging for radical surgery in malignant pleural mesothelioma?
D. Stewart (2003)
Pleural biopsies in undiagnosed pleural effusions; Abrams vs image-guided vs thoracoscopic biopsies
A. Bibby (2016)
Advances in the systemic therapy of malignant pleural mesothelioma
D. Fennell (2008)
Thoracic ultrasound in the diagnosis of malignant pleural effusion
N. R. Qureshi (2008)
J. Espinosa Arranz (1994)
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils
D. Torti (2011)
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.
R. Hassan (2010)
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
Abstract CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028
E. Alley (2015)
BTS statement on malignant mesothelioma in the UK, 2007
Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma
J. Creaney (2008)
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
Prostate-Specific Antigen-Based Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force
Kenneth Lin (2011)
A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.
M. O'Brien (2006)
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
L. Tanoue (2011)
S19 Interventions for the management of malignant pleural effusions
A. Clive (2015)
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
Thorac Dis 2013; 5: E254–E307
J mesothelioma (2013)
Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging--initial experience.
J. Coolen (2012)
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2016)
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.
M. Socinski (2002)
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
G. Beatty (2013)
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
Pleural mesothelioma: little evidence, still time to do trials
T. Treasure (2004)
A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions
K. Ong (2000)
Bleomycin versus Doxycycline: A Patient-Oriented Approach to Pleurodesis
D. K. Fuller (1993)
Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy.
H. Batırel (2016)
Advances in malignant mesothelioma.
B. Robinson (2005)
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
Talc pleurodesis. Prospective and randomized study. Clinical follow-up
N Manes (2000)
Malignant pleural mesothelioma: visual assessment by using pleural pointillism at diffusion-weighted MR imaging.
J. Coolen (2015)
Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
J. Creaney (2014)
What is the role of a specialist regional mesothelioma multidisciplinary team meeting? A service evaluation of one tertiary referral centre in the UK
A. Bibby (2016)
Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.
C. Dresler (2005)
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.
A. Rimner (2016)
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
Routes of asbestos exposure and the development of mesothelioma in an English region.
D. Howel (1997)
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
L. Emens (2015)
Cancer Anorexia‐Cachexia Syndrome: Current Issues in Research and Management
A. Inui (2002)
152: Suppl 6, S64–S71
F López-Ríos (1999)
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma
H. Pass (2006)
A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma
A. Nowak (2012)
Malignant mesothelioma 1982: review of 4710 published cases.
G. Hillerdal (1983)
Prostate-specific antigen-based screening for prostate cancer: an evidence update for the US Preventive Services Task Force. Agency for Research Health and Quality
K Lin (2011)
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary.
D. Maziak (2005)
A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial
Samal Gunatilake (2014)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
of Thoracic Surgeons for management of Malignant Pleural Mesothelioma
A. Scherpereel (2009)
The german thorotrast study: recent results and assessment of risks.
G. van Kaick (1999)
Medical and oncological management of malignant mesothelioma.
A. Bibby (2015)
Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010
C. Hooper (2010)
Antibody Pembrolizumab in Patients with Malignant Mesothelioma
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
Y. Ohta (1999)
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
K. Hollevoet (2010)
Assessing Quality of Life During Chemotherapy for Pleural Mesothelioma: Feasibility, Validity, and Results of Using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module
N. Hanna (2006)
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.
D. Sugarbaker (1996)
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
G. Ceresoli (2011)
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
pleural mesothelioma in the National Lung Cancer Audit in England and Wales
M Carbone (2015)
Pleurodesis using talc slurry.
L. Kennedy (1994)
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma
L. Lang-Lazdunski (2012)
The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
A. Renshaw (1997)
A new standard for malignant pleural mesothelioma
M. Zauderer (2016)
Malignant mesothelioma in south east England: clinicopathological experience of 272 cases.
D. Yates (1997)
Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals with a Noninvasive Proteomics-Based Surveillance Tool
R. Ostroff (2012)
A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The “SMART” Approach for Resectable Malignant Pleural Mesothelioma
B. Cho (2014)
The experience of mesothelioma in northern England.
H. Clayson (2007)
Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module.
A. Nowak (2004)
16TiPA phase II study combining tremelimumab and durvalumab (MEDI4736) immunomodulating antibodies in mesothelioma patients: The NIBIT-MESO-1 study
L. Calabrò (2015)
Prostate-specific antigen-based screening for prostate cancer: an evidence update for the US Preventive Services Task Force
K Lin (2011)
A phase II trial of surgical resection and adjuvant highdose hemithoracic radiation for malignant pleural mesothelioma
VW Rusch (2001)
Chemical Pleurodesis for Malignant Pleural Effusions
P. Walker-Renard (1994)
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
Department of Health. Mesothelioma Service Framework. Dept of Health Lung Cancer and Mesothelioma Advisory Group
Pilot and feasibility trial of immuno-gene therapy of malignant mesothelioma using intrapleural dlivery of adenovirus-interferon-α combined with chemotherapy
DH Sterman (2016)
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
R. Stahel (2015)
Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
R. Flores (2003)
Interventions for the management of malignant pleural effusions: a network meta-analysis.
A. Clive (2016)
Cisplatin and Gemcitabine in Malignant Pleural Mesothelioma: A Phase II Study
B. Castagneto (2005)
Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients with Malignant Mesothelioma
HL Kindler (2015)
multidisciplinary pain management group in a palliative care unit
AH Lebovits (2005)
MARS 2: A Feasibility Study Comparing (Extended) Pleurectomy Decortication Versus no Pleurectomy Decortication in Patients With Malignant Pleural Mesothelioma (MARS2). NCT02040272
Mesothelioma from the patient's perspective.
H. Clayson (2005)
Mesothelin-targeted immunotherapy CRS-207 in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM).
R. Hassan (2015)
Suffering in mesothelioma: concepts and contexts
H. Clayson (2003)
Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein.
J. Creaney (2005)
British Thoracic Society Standards of Care Committee
S. Blumenthal (2014)
Challenging the representations of cancer pain: experiences of a multidisciplinary pain management group in a palliative care unit.
E. Chapman (2005)
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
V. Rusch (1994)
Adaptation in Health and Illness, Sydney
N Hughes (2004)
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes
M. Carbone (2007)
Audit in England and Wales
M Carbone (2015)
‘It's all bad news’: the first 3 months following a diagnosis of malignant pleural mesothelioma
A. Arber (2013)
The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma.
A. Nakas (2008)
Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial.
N. Rahman (2015)
Computed Tomography, Positron Emission Tomography, Positron Emission Tomography/Computed Tomography, and Magnetic Resonance Imaging for Staging of Limited Pleural Mesothelioma: Initial Results
C. Plathow (2008)
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
G. Ceresoli (2008)
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010
M. Roberts (2010)
Computed Tomography of Pleural Lesions with Special Reference to the Mediastinal Pleura
O. Salonen (1986)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
M. Valsecchi (2015)
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma
S. Bydder (2004)
Treatment options for malignant pleural effusions: patient preference does matter.
N. Maskell (2012)
Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases.
M. Metintas (2002)
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010
M. Raza (2011)
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
R. Hassan (2014)
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
A. Mathy (2005)
Systematic review of trimodality therapy for patients with malignant pleural mesothelioma.
C. Cao (2012)
Molecular pathogenesis of malignant mesothelioma.
P. Rascoe (2012)
Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related Benign Pleural Disease: An Observational Pilot Study
H. Yildirim (2009)
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
Ai Cui (2014)
Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales.
P. Beckett (2015)
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
The lived experience of patients with pleural mesothelioma.
Nicola Hughes (2008)
Management of malignant pleural effusions.
M. Tattersall (1990)
Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial
N. Macleod (2015)
Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids
F. Lopez-Rios (2004)
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125
R. Hassan (2014)
Malignant pleural mesothelioma: computed tomography and correlation with histology.
J. Seely (2009)
Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis.
J. M. Porcel (2015)
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
P. Illei (2003)
Pleurectomy decortication for mesothelioma: The procedure of choice when possible.
R. Flores (2016)
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
The mesothelioma journey: developing strategies to meet the needs of people with mesothelioma, their family carers and health professionals involved in their care
R Hawley (2004)
Pleural procedures and thoracic ultrasound: British Thoracic Society pleural disease guideline 2010
T. Havelock (2010)
Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial
R. Rintoul (2014)
Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium.
K. Chang (1992)
Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.
R. Heelan (1999)
Efficacy and safety profile of autologous blood versus tetracycline pleurodesis for malignant pleural effusion
W. Keeratichananont (2015)
R Hassan (2014)
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
L. Calabrò (2015)
The mesothelioma surgery shift.
R. Flores (2016)
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guangwu Guo (2015)
Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial.
H. E. Davies (2012)
Simian virus 40-like DNA sequences in human pleural mesothelioma.
M. Carbone (1994)
Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma
D. P. M. van den Bogaert (2006)
Malignant Pleural Mesothelioma Caused by Environmental Exposure to Asbestos in the Southeast of Turkey: CT Findings in 117 Patients
A. Şenyiğit (2000)
Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.
J. Halstead (2005)
MARS 2: A Feasibility Study Comparing (Extended) Pleurectomy Decortication Versus no Pleurectomy Decortication in Patients With Malignant Pleural Mesothelioma (MARS2)
E. Lim (2016)
Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy
D. Sterman (2016)
NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma
D Torti (2015)
1074TiPRANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TREMELIMUMAB FOR SECOND-LINE AND THIRD-LINE TREATMENT OF UNRESECTABLE PLEURAL OR PERITONEAL MESOTHELIOMA.
A. Scherpereel (2014)
MRI and CT in the differential diagnosis of pleural disease.
J. Hierholzer (2000)
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
Early Breast Cancer Trialists' Collaborative Group (2011)
Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial
A. Clive (2016)
A very public death: dying of mesothelioma and asbestos-related lung cancer (M/ARLC) in the Latrobe Valley, Victoria, Australia.
S. Lee (2009)
Randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment of unresectable pleural or peritoneal mesothelioma.
M. Maio (2014)
Diagnostic accuracy of 18F-FDG-PET and PET/CT in the differential diagnosis between malignant and benign pleural lesions: a systematic review and meta-analysis.
G. Treglia (2014)
Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung Adenocarcinoma
K. Chang (1992)
Exposure to asbestos: psychological responses of mesothelioma patients.
A. Lebovits (1983)
Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
F. Bénard (1998)
Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
I. Opitz (2006)
SV40 induces mesotheliomas in hamsters.
C. Cicala (1993)
Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP 1 , NF 2 , CDKN 2 A , and CUL 1 in Malignant Pleural Mesothelioma
Guangwu Guo (2014)
This paper is referenced by
Early-stage Clinical Characterization of Malignant Pleural Mesothelioma
Y. Negi (2018)
2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth
I. Gerogianni (2019)
Asbestos , Mesothelioma and Lung Cancer : A Comment
S. Jargin (2017)
Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
A. Tsao (2019)
Management and Survival of Pleural Mesothelioma: A Record Linkage Study
G. Carioli (2018)
Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.
M. Cinausero (2018)
Diagnosis of Malignant Pleural Mesothelioma Using KNN
M. Kaur (2019)
Real-life treatment practice for malignant pleural mesothelioma in Belgium.
M. Rosskamp (2018)
Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin
Y. Nishinaga (2020)
Comparison of Efficiency of Pleurodesis Between Video Assisted Thoracoscopic Surgery (VATS) and Standard Thoracostomy
A. Alihodžić-Pašalić (2018)
Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review
Zehra Nur Töreyin (2020)
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma
Tania Villanova (2019)
Infectious Agents Associated with Mesothelioma
N. S. Lam (2019)
Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma
Stefania Augeri (2018)
Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma
V. Fontana (2019)
A review of the cohorts with environmental and occupational mineral fiber exposure
S. Metintaş (2019)
Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma
Kimberly A. Birnie (2017)
Malignant Pleural Effusion and Its Current Management: A Review
Kristijan Skok (2019)
Malignant Pleural Mesothelioma, Biphasic Type: An Unusual and Insidious Case of Rapidly Progressive Small Blue Cell Tumor
C. Salazar (2018)
CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.
M. Zeltsman (2017)
Malignant pleural mesothelioma : recognising an unmet need
Samal Gunatilake (2018)
The Formidable Metamorphosis of the Salamander’s Wool: Asbestos from Eternal Material to Awful Pathologies
L. Santarelli (2020)
Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma
E. Gamazon (2017)
Biomarkers in mesothelioma
D. Arnold (2018)
Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma
Jiale Wang (2018)
Catheter Tract Metastasis in Mesothelioma Patients with Indwelling Pleural Catheters: A Retrospective Cohort Study
M. A. Mitchell (2018)
Malignant Pleural Mesothelioma: an Update for Pulmonologists
C. Sidhu (2019)
Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.
Juuso Paajanen (2018)
Clinical diagnosis of malignant pleural mesothelioma.
A. Bianco (2018)
Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma
D. Xu (2019)
Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments
N. Kanellakis (2020)
Primary Tumors of the Pleura
R. Ledda (2020)See more